Stephen L Chan Selected Research

Fatigue

7/2018	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
1/2018	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
1/2016	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen L Chan Research Topics

Disease

74	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 01/2009
47	Neoplasms (Cancer) 02/2024 - 07/2007
8	Liver Neoplasms (Liver Cancer) 12/2023 - 02/2011
7	Nasopharyngeal Carcinoma 07/2023 - 10/2006
6	Hypertension (High Blood Pressure) 02/2024 - 12/2016
6	Hepatitis B 10/2016 - 06/2007
4	Vomiting 04/2024 - 03/2014
4	Nausea 04/2024 - 03/2014
4	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 07/2023 - 03/2012
4	Disease Progression 06/2023 - 01/2016
4	Liver Diseases (Liver Disease) 03/2022 - 09/2012
4	Infections 01/2016 - 06/2007
3	Multiple Organ Failure (MODS) 02/2024 - 01/2022
3	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2006
3	Diarrhea 12/2019 - 01/2016
3	Inflammation (Inflammations) 09/2019 - 01/2017
3	Colorectal Neoplasms (Colorectal Cancer) 12/2018 - 12/2013
3	Fatigue 07/2018 - 01/2016
2	Exanthema (Rash) 04/2024 - 01/2016
2	Fever (Fevers) 04/2024 - 01/2016
2	Asthenia 04/2024 - 02/2024
2	Microsatellite Instability 02/2024 - 03/2015
2	Varicose Veins (Varicose Vein) 02/2024 - 01/2022
2	Hepatic Encephalopathy 02/2024 - 01/2022
2	Chemical and Drug Induced Liver Injury 02/2024 - 01/2022
2	Tumor Lysis Syndrome 02/2024 - 01/2022
2	Adenocarcinoma 01/2020 - 05/2013
1	Cholangiocarcinoma 04/2024
1	Pruritus (Itching) 04/2024
1	Melanoma (Melanoma, Malignant) 02/2024
1	Sepsis (Septicemia) 02/2024
1	Respiratory Insufficiency (Respiratory Failure) 01/2023
1	Shock 01/2023
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2023
1	Alcoholic Fatty Liver 03/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Enterocolitis 01/2021
1	Lymphoma (Lymphomas) 01/2021
1	Hemorrhage 12/2020

Drug/Important Bio-Agent (IBA)

20	Sorafenib (BAY 43-9006)FDA Link 02/2024 - 05/2012
14	DNA (Deoxyribonucleic Acid)IBA 07/2023 - 10/2006
12	Biomarkers (Surrogate Marker)IBA 06/2022 - 07/2007
11	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2018
10	AlbuminsIBA 04/2021 - 01/2015
8	pembrolizumabIBA 09/2023 - 01/2018
8	BilirubinIBA 04/2021 - 06/2007
8	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2020 - 01/2009
6	cabozantinibIBA 03/2024 - 07/2018
5	atezolizumabIBA 04/2024 - 01/2022
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2024 - 01/2018
4	Alanine Transaminase (SGPT)IBA 02/2024 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2007
3	Bevacizumab (Avastin)FDA Link 04/2024 - 03/2022
3	Phosphotransferases (Kinase)IBA 10/2023 - 11/2014
3	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 09/2012
3	Cell-Free Nucleic AcidsIBA 01/2022 - 03/2015
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 07/2018 - 01/2016
2	spartalizumabIBA 04/2024 - 06/2022
2	Apoptosis Regulatory ProteinsIBA 02/2024 - 06/2022
2	tremelimumabIBA 12/2023 - 08/2022
2	durvalumabIBA 12/2023 - 08/2022
2	lenvatinibIBA 10/2023 - 01/2023
2	Tyrosine Kinase InhibitorsIBA 01/2023 - 03/2014
2	C-Reactive ProteinIBA 09/2019 - 01/2019
2	Histone MethyltransferasesIBA 01/2019 - 05/2013
2	Interleukin-8 (Interleukin 8)IBA 01/2019 - 01/2017
2	Antiviral Agents (Antivirals)IBA 01/2016 - 02/2012
2	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 01/2016 - 06/2013
2	Everolimus FDA Link 05/2015 - 06/2013
2	Fetal Proteins (Fetoprotein)IBA 03/2015 - 04/2014
2	belinostatIBA 09/2012 - 04/2010
2	Histone Deacetylase InhibitorsIBA 09/2012 - 04/2010
1	capmatinibIBA 04/2024
1	CS-1003IBA 02/2024
1	Monoclonal AntibodiesIBA 02/2024
1	apatinibIBA 01/2023
1	Gemcitabine FDA Link 01/2023
1	camrelizumabIBA 01/2023
1	Nucleic AcidsIBA 07/2022
1	roblitinibIBA 06/2022
1	NivolumabIBA 03/2022
1	Circulating Tumor DNAIBA 01/2022
1	SirtuinsIBA 01/2022
1	ChromatinIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 11/2021
1	Arginine (L-Arginine)FDA Link 10/2021
1	ArginaseIBA 10/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	CyanoacrylatesIBA 12/2020

Therapy/Procedure

25	Therapeutics 04/2024 - 02/2009
9	Drug Therapy (Chemotherapy) 01/2023 - 10/2006
5	Radiotherapy 01/2024 - 04/2011
4	Immunotherapy 01/2024 - 01/2020
3	Hepatectomy 05/2020 - 02/2017
3	Surgical Instruments (Clip) 01/2017 - 02/2011
2	Chemoradiotherapy 01/2023 - 09/2012
2	Liver Transplantation 01/2023 - 10/2015
2	Organ Transplantation 11/2022 - 01/2019
2	Transplantation 01/2021 - 10/2015
2	Aftercare (After-Treatment) 01/2019 - 01/2018